Evidence map›Paper›PMID 21482743›Full record

ArticleJAMA2011

A predictive model for progression of chronic kidney disease to kidney failure.

Navdeep Tangri, Lesley A Stevens, John Griffith, Hocine Tighiouart, Ognjenka Djurdjev, David Naimark, Adeera Levin, Andrew S Levey

Registry-linked trialAbstract readValidation Study
PubMed Publisher
In one paragraph

Article in JAMA, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06274710 (Open Access Digital CommunitY Promoting Self-Care, Peer Support, and HEalth LitEracy), which is not on this map. Cited by 674 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
674citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06274710 narecruitingnot on this mapstarted 2023, after this paper: background citation

Open Access Digital CommunitY Promoting Self-Care, Peer Support, and HEalth LitEracy (ODYSSEE) for Kidney Health (KH) Trial

TypeinterventionalSponsorUniversity Health Network, TorontoRan2023 to 2026Enrolled344ConditionsChronic Kidney DiseasesArmsODYSSEE-KH
3 · Its place in the literature

Who cites it

674 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025
    Trial
  5. The long-term effects of dapagliflozin in chronic kidney disease: a time-to-event analysis.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024
    Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Observational
  12. Article
  13. PREDICT Tool for Pregnancy-Associated CKD Progression.Kidney international reports · 2026
    Article
  14. Association of UACR and UPCR with kidney failure: analysis of observational data in patients with rare kidney diseases.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026
    Observational
  15. Article
  16. Article
  17. Article
  18. Observational
  19. Review
  20. A Microsimulation-Based Approach for Mitigating Societal Bias in Chronic Kidney Disease Data.Medical decision making : an international journal of the Society for Medical Decision Making · 2026
    Article

614 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Navdeep TangriDepartment of Medicine, Tufts Medical Center, 800 Washington St, PO Box 391, Boston, MA 02111, USA. ntangri@tuftsmedicalcenter.org
Lesley A Stevens
John Griffith
Hocine Tighiouart
Ognjenka Djurdjev
David Naimark
Adeera Levin
Andrew S Levey

Funding

Canadian Institutes of Health Research
6 · The paper itself

Abstract

contextChronic kidney disease (CKD) is common. Kidney disease severity can be classified by estimated glomerular filtration rate (GFR) and albuminuria, but more accurate information regarding risk for progression to kidney failure is required for clinical decisions about testing, treatment, and referral.

objectiveTo develop and validate predictive models for progression of CKD. DESIGN, SETTING, AND

participantsDevelopment and validation of prediction models using demographic, clinical, and laboratory data from 2 independent Canadian cohorts of patients with CKD stages 3 to 5 (estimated GFR, 10-59 mL/min/1.73 m(2)) who were referred to nephrologists between April 1, 2001, and December 31, 2008. Models were developed using Cox proportional hazards regression methods and evaluated using C statistics and integrated discrimination improvement for discrimination, calibration plots and Akaike Information Criterion for goodness of fit, and net reclassification improvement (NRI) at 1, 3, and 5 years.

main outcome measureKidney failure, defined as need for dialysis or preemptive kidney transplantation.

resultsThe development and validation cohorts included 3449 patients (386 with kidney failure [11%]) and 4942 patients (1177 with kidney failure [24%]), respectively. The most accurate model included age, sex, estimated GFR, albuminuria, serum calcium, serum phosphate, serum bicarbonate, and serum albumin (C statistic, 0.917; 95% confidence interval [CI], 0.901-0.933 in the development cohort and 0.841; 95% CI, 0.825-0.857 in the validation cohort). In the validation cohort, this model was more accurate than a simpler model that included age, sex, estimated GFR, and albuminuria (integrated discrimination improvement, 3.2%; 95% CI, 2.4%-4.2%; calibration [Nam and D'Agostino χ(2) statistic, 19 vs 32]; and reclassification for CKD stage 3 [NRI, 8.0%; 95% CI, 2.1%-13.9%] and for CKD stage 4 [NRI, 4.1%; 95% CI, -0.5% to 8.8%]).

conclusionA model using routinely obtained laboratory tests can accurately predict progression to kidney failure in patients with CKD stages 3 to 5.

Indexed as

Models, TheoreticalAgedAged, 80 and overAge FactorsAlbuminuriaBiomarkersCalciumCalibrationCohort StudiesDisease ProgressionFemaleForecastingGlomerular Filtration RateHumansKidney DiseasesMaleBiomarkersCalciumSerum Albumin

Identifiers

PMID21482743

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.